EMERYVILLE, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , today announced it will release its fiscal 2008 fourth quarter and year-end financial results on September 16, 2008.
The Company will also host a call to discuss its financial results. Details for the fiscal year-end call are as follows:
Telephonic Replay: A playback of the conference call will be available from 1:30 pm (ET) on September 16, 2008 to midnight (ET) on September 23, 2008. Reply number: 888-203-1112 U.S. / 719-457-0820 International Pass code: 2312764
The presentation at the Merriman Curhan Ford Investor Summit will take place on Monday, September 15, 2008 at 10:15 a.m. at the Mark Hopkins InterContinental Hotel in San Francisco. Access to the presentation can be found at: http://investor.shareholder.com/ntii/events.cfm
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company’s most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer’s and Huntington’s diseases and rights to receive payments on an approved drug for Alzheimer’s disease and an investigational drug in Phase 3 trials for brain swelling.
CONTACT: Matthew M. Loar, CFO of Neurobiological Technologies, Inc.,
+1-510-595-6000
Web site: http://www.ntii.com/
